As one of the main pathmechanisms of Alzheimer's disease (AD), amyloid-β (Aβ) is widely
considered to be the prime target for the development of AD therapy. Recently …

Alzheimer's disease (AD) is a complex disorder with unknown etiology. Currently, only
symptomatic therapy of AD is available, comprising cholinesterase inhibitors and N-methyl-d …

Alzheimer's disease (AD) is a neurological disorder that leads to dementia ie, progressive
memory loss accompanied with worsening of thinking ability of an individual. The cause of …

Alzheimer's disease (AD) is the most common form of dementia. While drugs that target
several pathways underlying AD have been proposed, effective treatments remain to be …

This study was aimed to study the interaction between purified irisin and rivastigmine tartrate
(RT), a cholinesterase inhibitor used in Alzheimer's therapy. Irisin mainly promotes brown fat …

Neuroinflammation plays a crucial role in the progression of Alzheimer's disease and other
neurodegenerative disorders. Overactivated microglia cause neurotoxicity and prolong the …

Background: Alzheimer's disease is a neurological disorder that causes brain cells to shrink
and die. Aim: Thirteen novel 'oxathiolanyl','pyrazolyl'and 'pyrimidinyl'indole derivatives were …

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by
cognitive decline and memory loss. Imipramine, a tricyclic antidepressant, has potent anti …

In this study, a series of new benzimidazole/1, 3, 5-triazine-2, 4-diamine hybrid derivatives
(9a–9l) were designed and synthesized. The potential multi-target profiles of these …

The complex pathogenesis of Alzheimer's disease (AD) has become a major obstacle in its
treatment. An effective approach is to develop multifunctional agents that simultaneously …